Suzuki, Y., Narita, M., and Yamazaki, N
You can read the full article at Tirzepatide, a dual receptor agonist of incretin hormones GIP and GLP-1, is being developed for type 2 diabetes and obesity treatment
GLP1 receptor agonist medications, such as semaglutide and tirzepatide, work on natural appetite and blood sugar pathways to help you feel fuller, reduce cravings, and support steady, sustainable fat loss
What it cannot yet tell us is whether managing those risks successfully translates into the broader healthspan outcomes this article has been building toward: preserved cognitive function, durable cardiovascular resilience, sustained lean mass, and reduced long-term disease burden
A pilot study of liraglutide, a GLP-1 receptor agonist, in patients with obesity and chronic migraine found that mean monthly headache days dropped from 19.8 to 10.7, a highly significant reduction